Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

RTTR - Ritter Pharmaceuticals Inc.

Previous close
0.448
0.448   100.000%

Share volume: 0
Last Updated: Fri 22 May 2020 10:00:00 PM CEST
Pharmaceuticals: Other: 0%

PREVIOUS CLOSE
CHG
CHG%
N/A
0.00
0.00%
This ticker is disabled and data are no longer maintained and up to date.
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
40%
Profitability 50%
Dept financing 39%
Liquidity 34%
Performance 31%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
0   0%
1 Month
0   0%
3 Months
0   0%
6 Months
0   0%
1 Year
0   0%
2 Year
0   0%
Key data
Stock price
$0.45
P/E Ratio 
N/A
DAY RANGE
$0.45 - $0.45
EPS 
-$0.61
52 WEEK RANGE
$0.15 - $1.27
52 WEEK CHANGE
-$45.17
MARKET CAP 
20.677 M
YIELD 
N/A
SHARES OUTSTANDING 
46.153 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.00
PUBLIC FLOAT 
$45,188,402
AVERAGE 10 VOLUME 
$31,092,736
AVERAGE 30 VOLUME 
$23,045,081
Company detail
CEO: Andrew J. Ritter
Region: US
Website: http://www.ritterpharmaceuticals.com
Employees: 5
IPO year: -
Issue type: Common Stock
Market: NASDAQ
Industry: Pharmaceuticals: Other
Sector: Health Technology

Ritter Pharmaceuticals, Inc. engages in the development of novel therapeutic products which modulate the human gut microbiome to treat digestive disorders and gastrointestinal diseases. It focuses on the development and commercialization of RP-G28. The company was founded by Andrew J. Ritter and Ira E. Ritter on March 29, 2004 and is headquartered in Los Angeles, CA.

Recent news